Recursion Pharmaceuticals (NASDAQ:RXRX) PT Lowered to $12.00

Recursion Pharmaceuticals (NASDAQ:RXRX) had its price objective lowered by stock analysts at KeyCorp from $16.00 to $12.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price target indicates a potential upside of 43.54% from the stock’s previous close.

Separately, Needham & Company LLC restated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $8.36 on Thursday. The stock’s fifty day moving average is $8.71 and its two-hundred day moving average is $9.78. Recursion Pharmaceuticals has a 52 week low of $4.97 and a 52 week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period last year, the business posted ($0.34) EPS. On average, research analysts anticipate that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

Insider Activity

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total value of $87,684.02. Following the transaction, the director now directly owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $8.78, for a total value of $26,340.00. Following the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,701,312.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total value of $87,684.02. Following the transaction, the director now owns 7,229,861 shares in the company, valued at $55,380,735.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 283,806 shares of company stock worth $2,272,027. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock worth $203,651,000 after buying an additional 13,777,689 shares during the last quarter. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after buying an additional 349,554 shares during the last quarter. Mubadala Investment Co PJSC purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $128,041,000. Kinnevik AB publ grew its stake in Recursion Pharmaceuticals by 14.4% during the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after buying an additional 1,500,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its stake in Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after buying an additional 1,159,023 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.